Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VNTH LOOKS LIKE A GOOD BUY RIGHT NOW
PPCH NEWS IMINENT
PPCH MOVING TODAY
BIEI ENGINES ROARING
WE ARE GOING DONT WAIT TO LONG BUY BIEI
RESULTS ON THE WAY BIEI
BIEI MOVING TODAY
BIEI NEWS Premier Biomedical Confirms Consolidation of Debt
EL PASO, TX--(Marketwired - May 31, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) reported today that it has consolidated its debt to one lender, a move that the company believes will minimize the toxic impact that having multiple lenders had on the market for its stock.
William A. Hartman, President and CEO of Premier Biomedical, stated, "We no longer have multiple lenders competing in the market with each other to sell their loan conversion stock and have turned the corner on this harmful financing which has depressed our stock price, and now have only one lender working with us in a more constructive partnership. This should improve our financial health and long term prospects."
BIEI COULD GO TODAY BEFORE DEAL ANNOUNCED
BIEI COULD GO TODAY BEFORE DEAL ANNOUNCED
HUGE NEWS DONE DEAL BIEI READ INTO IT EASY DIME COMING
HUGE NEWS DONE DEAL BIEI READ INTO IT EASY DIME COMING
NEWS NEWS NEWS BUY BIEI
WE HAVE A DEAL BIEI
DONT WASTE TO MUCH TIME BUY BUY BUY BIEI
BIG PHARMA ALMOST HERE HIT THE ASK OR GET LEFT BEHIND biei
BIG PHARMA ALMOST HERE HIT THE ASK OR GET LEFT BEHIND biei
WHAT ARE YOU WAITING FOUR BIEI
EASY DIME BIEI
Premier Biomedical Announces the Appointment of Dr. James Frincke to Chief Technical Officer Position
EL PASO, TX--(Marketwired - May 24, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) announced the appointment of Dr. James Frincke to the position of Chief Technical Officer effective immediately. In this role, Dr. Frincke will report to the President and CEO of Premier, William A. Hartman. Dr. Frincke will retain his current position as a member of the company's Scientific Advisory board, which reports to Premier's co-founder and Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, MD.
James Frincke, PhD, is a Research & Development Consultant at Red Spot Biosciences, LLC, currently providing pro bono consultation to physicians globally to discover treatments for diseases, such as Crohn's, Rheumatoid Arthritis, Alzheimer's, Parkinson's and Type 1 Diabetes. With over 30 years of experience in the biotechnology industry, Dr. Frincke has successfully managed major development programs for all phases of pharmaceutical development. Dr. Frincke received his PhD and BS degrees in Organic Chemistry from the University of California, Davis and has performed postdoctoral work in the area of drug metabolism.
Prior to Dr. Frincke's work as a consultant, he was VP of R&D Operations at Harbor Therapeutics, San Diego, CA, where he focused on treatments for age-related diseases. He is a world-renowned pharmaceutical scientist and has raised hundreds of millions of dollars to fund new and groundbreaking small molecule compound (monoclonal antibody), biological, and cellular and gene therapies. Dr. Frincke is a prolific inventor with 24 US and 120 International patents to his credit. He has also published 75 peer reviewed journal articles and has submitted 32 new drug applications to the FDA.
William A. Hartman, President and CEO of Premier Biomedical stated, "Dr. Frincke's outstanding level of drug development experience and business expertise will be put to full use to guide Premier through the complexities of the biomedical industry. Premier strongly believes that Dr. Frincke's larger role at Premier will be a tremendous help to guide and expedite our R&D programs currently underway at the University of Texas at El Paso (UTEP), and our many other technical and business related programs we are currently pursuing, and will be pursuing in the very near future."
BUY BUY BUY BIEI NEGOTIATIONS ALMOST DONE TRAIN RUMMBLING
BIEI TRAIN STARTED LEAVING THE STATION AWESOME NEWS YESTERDAY MUCH MORE TO COME
BIEI WE HAVE NEWS
10 BAGGER EASY BIEI BIG PHARMA COMING
BIEI ENGINES ARE ROARING
BIEI WILL SOON BE SCOOPED UP BY BIG PHARMA WALL STREET KEEPING THIS ONE QUIET
HOLY S--- BIEI MASSIVE BUYOUT IMINENT
BIEI ENGINES ARE IDLING
SOMETHING HUGE IS IN THE WORKS AT BIEI 2016 STOCK OF THE YEAR
BIEI NEGOTIATIONS DONE
BIEI BIEI BIE READY
Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
El Paso, TX -- (ReleaseWire) -- 04/25/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, "This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment."
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. "We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future," he said.
Contact William A. Hartman, President and CEO at 724-633-7033, PR@premierbiomedical.com.
Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
El Paso, TX -- (ReleaseWire) -- 04/25/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, "This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment."
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. "We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future," he said.
Contact William A. Hartman, President and CEO at 724-633-7033, PR@premierbiomedical.com.
Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
El Paso, TX -- (ReleaseWire) -- 04/25/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, "This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment."
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. "We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future," he said.
Contact William A. Hartman, President and CEO at 724-633-7033, PR@premierbiomedical.com.
Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
El Paso, TX -- (ReleaseWire) -- 04/25/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, "This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment."
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. "We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future," he said.
Contact William A. Hartman, President and CEO at 724-633-7033, PR@premierbiomedical.com.
CALLING ALL HEAVY HITTERS WE NEED SOME HELP ON BIEI WILL EXPLODE SOON
CALLING ALL HEAVY HITTERS WE NEED SOME HELP ON BIEI WILL EXPLODE SOON
BIEI M AND M ARE TRYING TO HOLD THIS WE NEED SOME HEAVY HITTERS THE TRAINS ENGINE IS ROARING
BIEI M AND M ARE TRYING TO HOLD THIS WE NEED SOME HEAVY HITTERS THE TRAINS ENGINE IS ROARING